R&D | December 01, 2025
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The initiative aims to connect startups and tech companies with its business units,
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
